8-K: Tevogen Bio Secures $36 Million Credit Line and Potential $14 Million Equity Investment

Tevogen Bio Holdings Inc. has entered into a term sheet for a $36 million credit facility and a contingent option for a $14 million private equity placement with The Patel Family, LLP.

Summary

• Tevogen Bio Holdings Inc. has agreed to a term sheet with The Patel Family, LLP for a $36 million unsecured line of credit.
• The credit facility allows Tevogen to borrow up to $1 million per month.
• Interest on the borrowed funds will be the lower of daily SOFR plus 2.00% or 7.00% per annum, payable quarterly in shares priced at $1.50 each.
• The loan matures 48 months after each draw date.
• Tevogen can prepay the loan in cash or shares, with share price at the greater of $1.50 or the closing price on the day before payment.
• The agreement also includes an option for the lender to purchase $14 million of Tevogen's common stock in a private placement.
• The private placement price will be at a 30% discount to the 10-day trailing volume weighted average price once the stock reaches at least $10.00 per share.
• Tevogen will issue 1,000,000 shares as a commitment fee after the definitive agreement is signed.
• The lender's ownership is capped at 9.99% of the common stock, with pre-funded warrants possible to avoid exceeding this limit.
• The total shares issued to the lender cannot exceed 19.99% of the outstanding shares at the time of the agreement.

Sentiment

Score: 7

Explanation: The document indicates a positive development with the securing of a credit facility and potential equity investment, but there are risks associated with the terms and conditions.

Positives

• The $36 million credit facility provides Tevogen with access to capital.
• The ability to draw up to $1 million per month offers flexibility in managing cash flow.
• The option for the lender to purchase $14 million in a private placement could provide additional capital if the stock price reaches $10.00.
• Prepayment of the loan is permitted without penalty.
• The interest rate is capped at 7.00%.

Negatives

• The interest on the credit facility is payable in shares of common stock, which could dilute existing shareholders.
• The private placement is contingent on the stock price reaching $10.00, which may not occur.
• The lender's ownership is capped at 9.99%, which may limit the amount of capital that can be raised from this source.
• The company is issuing 1,000,000 shares as a commitment fee.

Risks

• The company may not be able to draw the full $36 million if the private placement is exercised.
• The stock price may not reach the $10.00 threshold required for the private placement.
• The issuance of shares for interest payments and the commitment fee could dilute existing shareholders.
• The lender is an existing stockholder and affiliate, which could raise concerns about conflicts of interest.

Future Outlook

The company intends to finalize the definitive agreement by June 14, 2024, and will have access to the credit facility and the potential for a private placement if the stock price reaches the threshold.

Management Comments

• The company has entered into a binding term sheet with The Patel Family, LLP for a credit facility and potential private placement.

Industry Context

This type of financing is common for biotech companies seeking to fund research and development and operations. The use of a credit facility with a potential equity component is a typical structure for companies with fluctuating capital needs.

Comparison to Industry Standards

• The interest rate cap of 7.00% is within the typical range for unsecured credit facilities for companies of this size and stage.
• The private placement discount of 30% is a common incentive for investors in private placements.
• The use of a trailing volume weighted average price for the private placement is a standard method to determine a fair price.
• The ownership cap of 9.99% is a common provision to protect existing shareholders from excessive dilution.

Related Party Transactions

• The Patel Family, LLP is an existing stockholder and an affiliate of Manmohan Patel, a beneficial owner of at least 5% of the Company's common stock.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of shares for interest payments and the commitment fee.
• The credit facility provides the company with capital to fund operations and growth.
• The potential private placement could provide additional capital if the stock price reaches the threshold.

Next Steps

• The company will execute a definitive agreement by June 14, 2024.
• The company will issue 1,000,000 shares as a commitment fee.
• The company will begin drawing on the credit facility after the definitive agreement is signed.
• The company will monitor the stock price to determine if the private placement option will be exercised.

Key Dates

Keywords

credit facility, private placement, common stock, line of credit, equity investment, Tevogen Bio, financing, capital raise